Fosamax is a branded formulation of alendronate sodium that belongs to the bisphosphonate class of antiresorptive agents. It binds to bone mineral surfaces and inhibits the activity of osteoclasts by interfering with their intracellular signaling pathways. Absorption occurs mainly in the upper small intestine where the compound accumulates in bone tissue. Hydroxy groups in alendronate enable strong coordination with calcium in the hydroxyapatite lattice of bone leading to prolonged retention at resorption sites. The retained bisphosphonate undergoes slow release allowing continuous suppression of osteoclast mediated bone resorption. Pharmacodynamically the inhibition of farnesyl pyrophosphate synthase in osteoclast precursors prevents the formation of the mevalonate pathway which is essential for osteoclast function and the net clinical effect is a reduction in bone turnover and an increase in bone mineral density which lowers the risk of vertebral and non vertebral fractures.

Fosamax is a bisphosphonate medication used to treat osteoporosis by inhibiting bone resorption. It works by binding to bone mineral surfaces where it is internalized by osteoclasts. Once inside, the drug suppresses the activity of osteoclasts, reducing the rate of bone breakdown. This action helps to maintain or increase bone mineral density and lowers fracture risk. Fosamax is absorbed slowly after oral administration and reaches peak concentrations in the gastrointestinal tract. The drug exhibits a long skeletal half-life due to its affinity for bone tissue. Its targeted effect on bone remodeling provides a sustained therapeutic benefit in postmenopausal women and other high-risk patients.

Fosamax may irritate the stomach lining and cause heartburn or dyspepsia. It can lead to nausea, vomiting, or abdominal discomfort. Some users experience diarrhea or constipation. Oral ulcers or esophageal irritation may occur if the tablet is not taken with enough water. Musculoskeletal pain such as joint or muscle aches is reported. Headache or dizziness can occasionally appear. Skin reactions like rash or itching may develop. Mild flu-like symptoms including low fever or fatigue are possible.

Fosamax may cause stomach discomfort or heartburn in some patients. Patients sometimes experience irritation of the esophagus if the tablet is not taken upright with sufficient water. Occasional muscle or joint pain has been reported among users of the medication. Some individuals develop low blood levels of calcium, which can lead to tingling or numbness. Rarely, the drug is associated with atypical fractures of the thigh bone, although this occurs in a small fraction of cases. In a small number of cases, jaw bone problems such as osteonecrosis have been observed, especially after dental procedures. The most frequently reported side effects are mild and typically resolve without intervention.